HealthInvest Partners is a Stockholm-based fund management company founded by Carl Bennet and Anders Hallberg in 2006. The investment approach employed by the Swedish investment firm seeks to find companies with low valuations and possible catalysts to drive shareholder value. While only a few stock market participants know about this investment firm, HealthInvest Partners has performed incredibly well since inception. The firm’s HealthInvest Value Fund generated a net-of-fees return of 7% in 2015, after gaining 33% in 2014 and 35% in 2013. In fact, HealthInvest Value Fund has not suffered a down year in the past seven years or so, with its return reaching 22% per annum. Considering the exceptional performance of the Stockholm-based investment firm relative to the overall hedge fund industry in recent years, it seems like a great idea to have a look at the fund’s equity portfolio. HealthInvest Partners recently submitted the 13F filing for the first quarter of this year, so this article will discuss five new additions to the fund’s portfolio during the quarter.
We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).
OraSure Technologies Inc. (NASDAQ:OSUR)
– Number of shares held by HealthInvest Partners as of March 31: 405,771
– Value of HealthInvest’s holding as of March 31: $2.93 Million
HealthInvest Partners acquired a new stake of 405,771 shares in OraSure Technologies Inc. (NASDAQ:OSUR) during the March quarter, which was valued at $2.93 million at quarter-end. The company develops and markets products and specimen collection devices using proprietary technologies. OraSure Technologies completed the design of a rapid Ebola antigen test using its OraQuick platform in early 2015. The test has already received an Emergence Use Authorization (EUA) from the FDA for use by laboratories and facilities that are adequately equipped and trained to test Ebola infection. The company recognized $2.3 million in revenues last year from the sale of this product to the Centers for Disease Control and Prevention (CDC) for investigational use and field testing in Africa. OraSure Technologies reported consolidated net revenues of $119.7 million for 2015, which increased from $106.5 million in 2014. The company’s management anticipates consolidated net revenues in the range of $28.5 million-to-$29.0 million for the first quarter of the current year. Shares of OraSure have gained 14% since the beginning of 2016 and are up 8% in the past 12 months. Ken Fisher’s Fisher Asset Management reported owning 824,592 shares of OraSure Technologies Inc. (NASDAQ:OSUR) through the latest round of 13Fs.
